The bromobutyl rubber stopper for injectable sterile powder pharma grade API for tablet / capsule / granule / injection, oral & injectable is a pharmaceutical packaging component manufactured from a brominated isobutylene-isoprene copolymer. The base elastomer contains 1.8% to 2.2% bromine and is compounded with a sulfur-free cure system, a calcium stearate release system, and an optional fluoropolymer film on the product-contact plug face. Dimensional profiles follow ISO 8362-1:2018 neck finishes for 13 mm, 20 mm, and 32 mm vials. Model coding identifies the polymer, neck diameter, slot configuration, and film: BIIR-20-3S-ETFE denotes a bromobutyl closure for 20 mm necks with three venting slots and ETFE coating, while BIIR-13-F1 denotes a flanged, non-slotted serum closure for 13 mm vials. The same material is used as a bulk API container closure for tablets, capsules, granules, and oral or injectable intermediates where low water-vapor transmission, low oxygen permeation, and controlled extractables are required. The closure is not a formulation ingredient; it is a critical packaging material qualified as part of the container closure system.

When the Closure Must Function After Lyophilization

During freeze drying, slotted bromobutyl stoppers are partially seated and held in the lyophilization chamber; the slots provide vapor pathways for sublimation. Shelf temperatures during primary drying are commonly controlled between −45 °C and +30 °C, and the stopper must return sufficient sealing force when the shelves compress the closure at the end of the cycle. Production-scale lyophilizer data show that final headspace gas composition in the sealed vial depends on stopper moisture content, slot geometry, and chamber backfill pressure. Stoppers are washed in rotary vial washers and steam sterilized at 121 °C for 30 min; residual moisture after drying is held at ≤0.5% w/w because higher retained moisture transfers into the lyophilized cake or raises the headspace dew point. On high-speed capping stations operating above 450 vials per minute, residual surface moisture above 0.8% w/w has been associated with intermittent capping pressure loss and glass flange microcracks in 13 mm neck formats. For dry heat sterilization at 160 °C for 2 h, the closure is pre-dried to ≤0.2% w/w; otherwise volatile decomposition products can exceed the UV absorbance limit of Ph. Eur. 3.2.9.

Needle penetration and fragmentation are critical for reconstitution. Repeated penetration with 21G needles is assessed according to ISO 8871-5:2016. A typical release test requires no visible fragmentation in 8 of 10 penetrated stoppers, and pierced closures must maintain a 0.5 bar internal nitrogen pressure differential without leakage. Because bromobutyl vulcanizates undergo post-cure changes, these tests are performed after terminal steam sterilization rather than on as-molded closures. Penetration force with a 21G needle is typically 1.2 N to 3.5 N for fluoropolymer-coated closures and can exceed 6 N for uncoated closures after multiple holes. This higher force is a recognized limitation when reconstitution is performed with large-bore or blunt drawing needles.

How Does Bromobutyl Differ From Chlorobutyl in Injectable Powder Service?

Bromobutyl closures differ from chlorobutyl closures primarily in halogen reactivity and crosslink density. The brominated isoprene unit cures more readily, permitting a low-zinc or zinc-free cure and lower residual metal extractables. Technical data sheets for comparable 20 mm closures report oxygen permeability coefficients from 2.5 × 10⁻¹⁷ to 4.0 × 10⁻¹⁷ mol·m·m⁻²·s⁻¹·Pa⁻¹ at 23 °C for bromobutyl, while chlorobutyl formulations of equal thickness fall from 4.0 × 10⁻¹⁷ to 7.0 × 10⁻¹⁷ mol·m·m⁻²·s⁻¹·Pa⁻¹. Moisture vapor transmission normalized to 1 mm thickness at 40 °C and 75% relative humidity is generally 0.4 g·mm/m²·day to 0.8 g·mm/m²·day for bromobutyl and 0.9 g·mm/m²·day to 1.4 g·mm/m²·day for chlorobutyl. These differences support the use of bromobutyl for freeze-dried powders with headspace oxygen targets below 2% v/v and for moisture-sensitive APIs stored in high-humidity zones.

Against polyisoprene, bromobutyl provides lower gas and moisture permeation but higher needle penetration force and greater sensitivity to ionizing radiation. Polyisoprene closures may offer easier needle insertion and lower fragmentation, but their water vapor transmission can exceed 4 g·mm/m²·day under tropical storage while bromobutyl remains below 0.6 g·mm/m²·day under the same conditions. Silicone closures have excellent low-temperature flexibility but oxygen permeability two to three orders of magnitude higher than bromobutyl, making them unsuitable for oxygen-sensitive sterile powders. EPDM closures are less resistant to aliphatic solvents and may generate higher volatile organic extractables after repeated autoclaving, whereas bromobutyl after post-cure annealing shows stable extractive profiles through 121 °C for 30 min for at least 3 cycles.

Extractable and Leachable Control Boundaries

The product is controlled against Ph. Eur. 3.2.9, USP 〈381〉, and ISO 8871-1:2016. Aqueous extraction is performed at 121 °C for 30 min; the extract is examined for pH shift, reducing substances, UV absorbance at 220 nm, and residue on evaporation. For a 20 mm closure, residue on evaporation is typically controlled to ≤2.0 mg per closure, and UV absorbance at 220 nm is held below 0.20 AU in a 10 mm path cell. The fluoropolymer film reduces contact of the elastomer with the drug, lowering extractable bisphenol A diglycidyl ether and nitrosamine-related impurities; however, the film increases needle penetration force by 0.5 N to 1.5 N relative to uncoated material.

In sterile dry powder filling of injectable APIs, the closure is supplied as ready-to-sterilize; it is transferred through a depyrogenation tunnel or autoclave bag and presented to the capping station without further washing. For lyophilized products, the closure is inserted to the first notch after dose fill, then fully seated by shelf compression. The residual moisture in the stopper after washing therefore defines not only chemical purity but also the mechanical friction against the vial neck and the chamber backfill gas diffusion rate.

The same closure is used in oral API containers for tablets, capsules, and granules when moisture protection and low leachable metals are specified. In that service, a 20 mm bromobutyl stopper with a fluoropolymer liner is seated into 100 mL to 500 mL glass bottles under aluminium caps with torque of 1.5 N·m to 2.5 N·m. Seal quality is verified by vacuum decay using ASTM F2338-09 at 20 kPa pressure differential. The closure does not contact the oral dosage form directly and is therefore not required to meet parenteral extractive limits, but the same extraction and volatile controls are applied to prevent cross-contamination in shared packaging areas.

Manufacturing-Line Handling Is Not Uniform Across Neck Sizes

Rotary washing machines with ultrasonic prewash use silicone-free wash cycles for bromobutyl closures. Excess surface silicone can reduce the coefficient of friction below 0.20, causing stopper bridging in feed chutes on lines running above 300 vials per minute; insufficient silicone raises hopper jams and capping misalignment on continuous-motion cappers. A washed and dried stopper typically exhibits a coefficient of friction between 0.25 and 0.45 against a stainless steel chute. In 13 mm neck formats, tipped-stopper defect rates have exceeded 2% on older inline filling equipment when the coefficient falls below 0.20. Dry heat sterilization and dry powder isolator environments generate static charge on uncoated bromobutyl; this is controlled with ionizing air bars at the hopper discharge and by using fluoropolymer-coated plug faces for 20 mm and 32 mm closures.

Gamma irradiation is not the default sterilization route. Published data for this specific bromobutyl closure formulation at irradiation doses above 25 kGy are limited; steam at 121 °C for 30 min or dry heat at 160 °C for 2 h after pre-drying is specified unless the user qualifies the exact closure, container, and drug product system. The material should not be combined with amine-based additives, strong oxidizing media, or low-molecular-weight ester plasticizers because these compounds can alter the cure network, increase permeability, or extract into the drug solution.